This category page covers biotechnology and pharmaceutical companies developing autophagy-enhancing and lysosomal modulation therapies for Alzheimer's disease. Autophagy — the cellular process of degrading and recycling damaged proteins and organelles — is impaired in AD, contributing to the accumulation of toxic protein aggregates including amyloid-beta plaques and tau tangles. Restoring or enhancing autophagy represents a fundamentally different therapeutic approach than directly targeting Aβ or tau[@autophagy2024].
The main autophagy targets in AD include:
Mechanism: Selective mTORC1 inhibitor (small molecule)
Clinical Stage: Phase 1 (for neurological applications)
Background: Navitor is developing NV-2526, a selective mTORC1 inhibitor designed to promote autophagy in neurons. mTORC1 inhibition releases the brake on autophagy initiation, enabling cells to clear protein aggregates. Unlike rapamycin (broad mTOR inhibitor), NV-2526 is designed for CNS specificity and safety[@navitor2024].
Key Science:
Mechanism: Autophagy-lysosome pathway enhancers (small molecules)
Clinical Stage: Preclinical
Background: Casma is developing a platform of small molecules that enhance autophagosome formation and lysosomal function. Their approach targets the autophagy machinery directly rather than via mTOR modulation[@casma2024].
Mechanism: Cannabinoid receptor modulation (SCI-100)
Clinical Stage: Phase 2 (AD program)
Background: SciSparc's SCI-100 is a CB2 receptor agonist that enhances autophagy in neuronal cells. Cannabinoid receptor activation promotes autophagic clearance of Aβ and tau in preclinical models[@scisparc2024].
Mechanism: TREM2 agonism (promotes microglial autophagy)
Clinical Stage: Phase 2 (latozinemab)
Background: While primarily a TREM2 agonist for neuroinflammation, TREM2 signaling also promotes microglial autophagy and lysosomal function. Alector's approach may enhance the brain's natural clearance mechanisms[@alector2024].
| Company | Mechanism | Stage | Notes |
|---|---|---|---|
| Calico Life Sciences | mTOR modulation, TFEB activation | Research | Alphabet-backed, focused on longevity |
| Life Biosciences | Chaperone-mediated autophagy enhancement | Preclinical | Focusing on CMA upregulation in aging |
| AbbVie | TFEB activators | Discovery | Broad autophagy platform |
| Roche | Lysosomal acidifiers | Preclinical | V-ATPase modulators for lysosomal function |
| Acumen | Autophagy enhancers | Discovery | Novel small molecule approach |
| Target | Drug | Company | Mechanism | Stage |
|---|---|---|---|---|
| mTORC1 | NV-2526 | Navitor | Inhibits mTORC1 to release autophagy brake | Phase 1 |
| TFEB | Various | Multiple | Promotes TFEB nuclear translocation | Preclinical |
| BECN1 | CSTI-100 | Casma | Enhances autophagosome nucleation | Preclinical |
| CB2 | SCI-100 | SciSparc | Cannabinoid-mediated autophagy enhancement | Phase 2 |
| V-ATPas | V-ATPase modulators | Roche | Restores lysosomal acidification | Preclinical |
| CMA | LISC-52 | Life Biosciences | Enhances chaperone-mediated autophagy | Preclinical |
mTOR (mechanistic target of rapamycin) is a master regulator of cell growth and metabolism. mTORC1 specifically inhibits autophagy by phosphorylating and inactivating ULK1 (the initiator of autophagosome formation) and by preventing TFEB nuclear translocation. In AD, mTORC1 activity is elevated in neurons, suppressing autophagy and contributing to protein aggregate accumulation. Rapamycin and related mTOR inhibitors have shown neuroprotective effects in AD models, but off-target effects limit clinical use.
TFEB (transcription factor EB) is the master regulator of lysosomal and autophagic gene expression. When mTORC1 is inhibited, TFEB translocates to the nucleus and drives expression of genes encoding autophagy proteins, lysosomal enzymes, and lysosomal membrane proteins. TFEB activation can dramatically enhance the cell's capacity to degrade proteins.
CMA selectively degrades proteins with a KFERQ-like motif. In AD, CMA is impaired, leading to accumulation of tau and other aggregating proteins. Enhancing CMA could selectively clear toxic proteins while sparing normal cellular components.
Late-stage AD features severe lysosomal dysfunction, including:
Therapies targeting lysosomal health address these downstream defects.
Preclinical evidence for autophagy in clearing disease-relevant proteins:
| Protein | Model | Intervention | Result |
|---|---|---|---|
| Aβ | APP/PS1 mice | Rapamycin | Reduced plaques, improved cognition |
| Aβ | 3xTg mice | mTOR inhibition | Reduced intracellular Aβ, improved memory |
| Tau | P301S mice | mTOR inhibition | Reduced tau aggregation, improved survival |
| Tau | rTg4510 mice | TFEB activation | Reduced tau pathology |
| Aβ/Tau | iPSC-AD neurons | Autophagy enhancers | Reduced aggregates, restored neuronal function |
The autophagy modulation field for AD is still early, with no approved therapies. Key differentiators:
| Approach | Advantages | Risks |
|---|---|---|
| mTORC1 inhibitors | Well-validated mechanism, clear pathway | Off-target effects, immunosuppression |
| TFEB activators | Promotes lysosomal biogenesis | May be too broad |
| Direct autophagy enhancers | Targeted to autophagy machinery | Unclear specificity |
| Lysosomal modulators | Addresses downstream defect | May be too late in disease |